Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Launched by UNIVERSITY OF COLOGNE · Apr 6, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new personalized treatment approach for early-stage unfavorable classical Hodgkin lymphoma (cHL), a type of blood cancer. The goal is to see if this individualized treatment, which includes a type of therapy called checkpoint inhibition, is both effective and easy for patients to tolerate. The trial is currently welcoming participants between the ages of 18 and 60, as well as those 61 and older who meet specific health criteria. To be eligible, participants must have a first diagnosis of cHL that is considered early-stage and has certain risk factors.

If you join this trial, you can expect to receive a tailored treatment plan that fits your specific condition. The researchers are focusing on ensuring that the treatment is both effective in fighting the cancer and manageable for patients. It’s important to note that individuals with certain other types of lymphoma or specific complications in the nervous system are not eligible for this study. This trial represents an opportunity to explore new treatment options that could improve care for people facing this diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-60 for the main trial cohort
• • Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for the exploratory cohort
• • First diagnosis of treatment-naïve cHL
• * Early-stage unfavorable disease (i.e. stage IA, IB and IIA with risk factors a-d, stage IIB with risk factors c-d):
• • 1. large mediastinal mass
• • 2. extranodal lesion(s)
• • 3. elevated erythrocyte sedimentation rate
• • 4. ≥ 3 nodal areas
• Exclusion Criteria:
• • Presence of nodular-lymphocyte predominant Hodgkin lymphoma, grey-zone lymphoma and/or central nervous system involvement of lymphoma